Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 20;38(5):496-500.
doi: 10.3760/cma.j.cn501120-20210703-00234.

[Research advances of the roles of sphingosine-1-phosphate in acute lung injury]

[Article in Chinese]
Affiliations
Review

[Research advances of the roles of sphingosine-1-phosphate in acute lung injury]

[Article in Chinese]
M Y Wang et al. Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi. .

Abstract

Sphingosine-1-phosphate (S1P) is the main metabolite produced in the process of phospholipid metabolism, which can promote proliferation, migration, and apoptosis of cells, and maintain the barrier function of vascular endothelium. The latest researches showed that S1P can alleviate acute lung injury (ALI) and the inflammation caused by ALI, while the dosage of S1P is still needed to be considered. Mesenchymal stem cells (MSCs) have been a emerging therapy with potential therapeutic effects on ALI because of their characteristics of self-replication and multi-directional differentiation, and their advantages in hematopoiesis, immune regulation, and tissue repair. S1P can promote differentiation of MSCs and participate in immune regulation, while MSCs can regulate the homeostasis of S1P in the body. The synergistic effect of S1P and MSC provides a new treatment method for ALI. This article reviews the production and biological function of S1P, receptor and signal pathway of S1P, the therapeutic effects of S1P on ALI, and the research advances of S1P combined with MSCs in the treatment of ALI, aiming to provide theoretical references for the development of S1P targeted drugs in the treatment of ALI and the search for new combined treatment schemes for ALI.

1-磷酸鞘氨醇(S1P)是磷脂代谢过程中的主要产物,具有促进细胞增殖、迁移、凋亡,维持血管内皮屏障功能等作用。最新研究显示,S1P能够减轻急性肺损伤(ALI)及其引起的炎症等,但在使用剂量上仍需斟酌。间充质干细胞(MSC)因具有自我复制、多向分化等特点,且在造血、免疫调控、组织修复方面具有优势,已成为新兴疗法,对ALI有潜在治疗作用。S1P能促进MSC分化,并参与免疫调节,而MSC能够调节机体内S1P的稳态,二者的协同作用为ALI提供新的治疗方法。该文对S1P的产生及生物学功能、S1P受体及信号通路、S1P对ALI的治疗效果及S1P与MSC联合治疗ALI的研究进展进行综述,以期为开发S1P靶点药物治疗ALI及寻找新的ALI联合治疗方案提供理论参考。.

PubMed Disclaimer

Conflict of interest statement

利益冲突 所有作者均声明不存在利益冲突

Similar articles

Cited by

References

    1. Mokra D, Kosutova P. Biomarkers in acute lung injury. Respir Physiol Neurobiol. 2015;209:52–58. doi: 10.1016/j.resp.2014.10.006. - DOI - PubMed
    1. Combes A, Pesenti A, Ranieri VM. Fifty years of research in ARDS. Is extracorporeal circulation the future of acute respiratory distress syndrome management? Am J Respir Crit Care Med. 2017;195(9):1161–1170. doi: 10.1164/rccm.201701-0217CP. - DOI - PubMed
    1. 俞 正秋, 马 春芳, 蔡 宛如. 急性肺损伤/急性呼吸窘迫综合征治疗进展. 中国现代医生. 2021;59(13):189–192.
    1. Noone PM, Reddy SP. Recent advances in dead cell clearance during acute lung injury and repair. Fac Rev. 2021;10:33. doi: 10.12703/r/10-33. - DOI - PMC - PubMed
    1. Fan Y, Chen J, Liu D, et al. HDL-S1P protects endothelial function and reduces lung injury during sepsis in vivo and in vitro. Int J Biochem Cell Biol. 2020;126:105819. doi: 10.1016/j.biocel.2020.105819. - DOI - PubMed

LinkOut - more resources